Ionis Pharmaceuticals Stock News

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 76.25% and 30.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Ionis Pharmaceuticals (NASDAQ:IONS) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $0.31 and the consensus…

Benzinga’s Daily Brief On Trending Tickers highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks. The

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks

During the last session, Ionis Pharmaceuticals Inc. (NASDAQ:IONS)s traded shares were 0.74 million, with the beta value of the company hitting 0.85. At the end of the trading day, the stocks price was $32.27, reflecting an intraday loss of -1.44% or -$0.47. The 52-week high for the IONS share is $58.46, that puts it down Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Rose 22.4% From Its 52-Week Low; YTD Numbers Rose 6.05% Here Are Some Things To Keep In Mind Read More »

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

These funds can take some of the risks out of these exciting but sometimes dangerous sectors.

Is this discontinued drug from Pfizer nothing more than a drop in the bucket?

CARLSBAD, Calif., Feb. 10, 2022 /PRNewswire/ – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, February 24th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2021 financial results as well as report on pipeline…

CARLSBAD, Calif., Feb. 10, 2022 /PRNewswire/ – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, February 24 th at 11:30 a.m.

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 mon

Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.

Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.

Ionis Pharmaceuticals Inc IONS announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that c

The drugmaker is throwing in the towel on a once-promising pipeline candidate.